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Abstract 
 
Verrucous carcinoma of the oral cavity (OVC) is considered a subtype of classical 
oral squamous cell carcinoma (OSCC). Diagnosis is problematic, and additional 
biomarkers are needed to better stratify patients. To investigate their molecular 
signature, we performed low coverage copy number sequencing on 57 OVC and 
exome and RNA sequencing on a subset of these and compared the data to the 
same OSCC parameters. Copy number results showed that OVC lacked any of the 
classical OSCC patterns such as gain of 3q and loss of 3p and demonstrated 
considerably fewer genomic rearrangements compared to the OSCC cohort. OVC 
and OSCC samples could be clearly differentiated. Exome sequencing showed that 
OVC samples lacked mutations in genes commonly associated with OSCC (TP53, 
NOTCH1, NOTCH2, CDKN2A and FAT1). RNA sequencing identified genes that 
were differentially expressed between the groups. In silico functional analysis 
showed that the mutated and differentially expressed genes in OVC samples were 
involved in cell adhesion and keratinocyte proliferation, while those in the OSCC 
cohort were enriched for cell death and apoptosis pathways. 
This is the largest and most detailed genomic and transcriptomic analysis yet 
performed on this tumour type, which, as an example of non-metastatic cancer, may 
shed light on the nature of metastases. These three independent investigations 
consistently show substantial differences between the cohorts. Taken together they 
lead to the conclusion that OVC is not a subtype of OSCC, but should be classified 
as a distinct entity.  
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Introduction  
An aim of the detailed analysis of cancer genomes is to discover genomic features 
that are prognostic for disease outcome and predictive of treatment response. 
Historically, genetic changes at specific loci have provided this information 1 but 
more recently examination of the whole genome has been shown to have predictive 
power. We have illustrated the use of whole genome architecture to predict survival 
in squamous cell lung carcinoma patients 2. Genomic analysis has been used to 
reclassify breast cancer tumours providing better prediction of disease outcomes 3 
and recently, molecular classification using multiple platforms has effectively 
clustered subtypes across different cancer tissue types,  identifying unexpected 
associations that could influence choice of therapy 4. 
Patients with oral cancer would benefit from a biomarker that would indicate 
outcome, specifically regional metastatic spread. A ‘‘wait and see’’ approach could 
expose patients to the risk of under treatment of occult node metastases. 
Unnecessary elective neck dissection does have an associated morbidity and may 
remove or destroy a natural barrier to cancer spread. This is of outmost importance 
when considering the high risk of developing second primary tumours in case for oral 
cancer patients 5.  
OVC is a case in point. The WHO classification of oral cancer recognises verrucous 
carcinomas as a subtype of oral epithelial cancer 6. It has a different morphological 
appearance being exophytic in its growth patterns and a different behaviour in that it 
is not associated with metastatic spread 7. However some classical oral squamous 
carcinomas can have a verrucous appearance creating diagnostic uncertainty and 
subsequent dilemmas of clinical management 8.  We questioned whether genomic 
profiling could distinguish true verrucous carcinomas from classical squamous 
carcinomas that may have a verrucous appearance to produce a useful diagnostic 
biomarker. We used FFPE blocks as a source of tumour DNA for both next 
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generation sequencing at low coverage to generate copy number profiles 2, and 
exome sequencing.  Additionally, RNA was isolated from the same blocks and 
transcription profiles generated using RNA-seq. Parallel analyses were undertaken 
for classical oral squamous cell carcinoma. Comparing the profiles, we found that 
true verrucous carcinomas were easily distinguishable from their classical 
counterparts; indeed no overlap was seen in patterns of genomic damage and 
transcriptional profiles could be used to clearly separate samples into their groups. 
Unlike classical oral tumours, TP53 was not inactivated either by mutation or HPV 
infection 9 leading us to conclude that verrucous carcinoma should be considered a 
separate entity from classical squamous carcinoma.   
 
Materials and methods 
Sample selection  
Four different sources of Formalin Fixed Paraffin-Embedded (FFPE) tissue were used in 
this study. Fifteen OVC FFPE blocks were retrieved from the Pathology Department, St 
James’s University Hospital, Leeds, UK; 15 OVC FFPE blocks were provided by the 
Pathology Division, Queen Victoria Hospital, West Sussex, UK; 40 OVC samples were 
provided by the Pathology Division, University of Torino, Italy and seven OVC FFPE 
blocks were provided by the Department of Pathology, National Guard Hospital, Saudi 
Arabia. Written informed consent was obtained from all patients for the use of their tissue 
in this research and the study approved by local ethics committees (REC ref no 
07/Q1206/30 and 08/H1306/127). In total, 77 OVC lesions were identified and all 
diagnoses were confirmed by the study pathologist (AH). World health organisation 
(WHO) definitions and criteria were used for the histological diagnosis of OVC 6 (Figure 
1a and b). Squamous cell carcinoma lesions with verrucous appearance were classified 
as squamous cell carcinoma with papillary architecture 6 (Figure 1b and c). Five of these 
samples were analysed by copy number sequencing (Figure 2d), following which the 
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samples were excluded from further analysis. For different reasons, such as low yields of 
the extracted DNA and failed library preparation, 57 cases out of 77 were suitable for 
NGS copy number analysis, all of which have previously been shown not to contain 
Human Papilloma Virus (HPV) DNA 9. Of these, 12 cases with adequate tissue were 
used and successfully prepared for RNA and exome sequencing. From our ongoing 
study of head and neck squamous cell carcinoma (HNSCC) 10, we identified 45 HPV 
negative OSCC patients for copy number (CN) analysis, 16 for RNA-seq, and 20 for 
exome sequencing. Table 1S summaries the clinical data from these patients.  
 
DNA isolation for copy number analysis (CN) 
Tissue blocks were cut into sections and epithelial cells of interest macrodissected as 
described previously using stained slides as a guide 9. DNA extraction was performed on 
macro-dissected FFPE tissue using Qiagen DNA extraction kits (Qiagen, Sussex, UK) 
according to manufacturer’s instructions. DNA concentration and purity were quantified 
using a Nanodrop UV spectrophotometer: Nanodrop-8000 (Thermo Scientific, UK). 
Additionally, double-stranded DNA concentration was precisely measured using the 
Quant-iT PicoGreen dsDNA BR assay (Invitrogen, UK). 
 
Nucleic acid isolation for exome and RNA sequencing  
DNA and RNA were simultaneously isolated from further macrodissected tissue from the 
same patients using the AllPrep DNA/RNA FFPE kit (Qiagen, Sussex, UK) according to 
manufacturer’s instructions. Nucleic acid concentration and purity were quantified as 
before. RNA concentration was measured using The Qubit RNA Assay kit (Invitrogen, 
UK). 
 
Copy number analysis: library preparation, sequencing and data analysis 
DNA libraries were prepared following two previously described protocols: for the Illumina 
Genome analyser GAIIx sequencer 2, and later, using NEBnext library preparation kits 
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(New England BioLabs, UK) for the Illumina HiSeq 2500 9. Samples were pooled for 
cluster amplification and multiplexed up to 20 samples per lane for Illumina Genome 
analyser GAIIx single end sequencing, and up to 40 samples per lane and paired-end 
sequenced (2X100bp) on an Illumina HiSeq 2500. 
Sample reads were split into separate files according to tags and aligned to the human 
reference genome. A control sample was pooled from a group of 20 British normal 
individuals downloaded from the 1000 Genomes Project 11. Reads were trimmed of 
adaptors using cutadapt 12, aligned to the human genome (hg19) using BWA 13. Genomic 
copy number was analysed using CNAnorm 14. The genome was split into 400Kb 
windows, and the ratios of tumour and normal read counts per window were counted and 
normalised. 
Cumulative frequency karyograms were constructed for the OVC and OSCC cohorts by 
counting how many samples had gain and loss for each position along the genome. The 
copy number profiles of OVC and OSCC were also categorised using GISTIC2 15, 
identifying genes within copy number altered regions, and generating segmented copy 
number heat maps.  
The ability to distinguish OVC and OSCC samples using their copy number profiles was 
also tested using a novel logistic regression technique16. Each sample was removed from 
the total data set in turn. The remaining samples were then used to build a predictive 
model. Each genomic window was given a score based on its ability to distinguish the 
two groups. The model was then applied to the test sample and a subtype prediction was 
made. This process was repeated for each sample, with the model being retrained on all 
other samples each time, so that no sample was predicted based on a training set of 
which it was a part. 
 
Exome sequencing: library preparation, sequencing and data analysis 
DNA sequencing libraries were separately prepared using the NEBNext singleplex 
library preparation kit (New England BioLabs, UK) and then exome DNA was 
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captured with Agilent exome capture kit (Agilent technologies Inc., USA). Briefly, 
750ng of each library was hybridized for target enrichment, followed by washing, 
indexing and 10-cycle PCR amplification. Indexed samples were pooled up to four 
samples per lane and paired-end sequenced (2X100bp) on an Illumina HiSeq 2500. 
Sequencing was performed to an average of 90X coverage. Reads were trimmed 
using cutadapt 12 to aligned to the human genome (hg19) using BWA 13. PCR 
duplicates were removed using Picard (http://picard.sourceforge.net), and indel 
realignment and quality score calibration performed using GATK 17. Variant calling 
was performed by Varscan2 in somatic mode 18, and variant consequences were 
then predicted using the Variant Effect Predictor 19. Variants were filtered using a 
number of criteria to enrich the mutation list for functionally important genes: 
Mutations had to pass a Varscan2 Phred somatic score of threshold of 15 (p-value of 
less than 0.05); mutations had to be present in over 50% of tumour cells, calculated 
taking into account tumour cell percentages and local copy number, as well as 
absent in the matched normal sample; mutations that have a predicted possible 
consequence on protein function (deleterious, splice variant, probably deleterious, 
possibly deleterious, stop gained).  
The DAVID (Database for Annotation, Visualisation and Integrated Discovery) 
Bioinformatics Database 6.7 was used to produce lists of significantly enriched 
pathways from the mutated genes passing filters in the OVC and OSCC cohorts 20.  
 
RNA-seq: library preparation, sequencing and data analysis 
cDNA Libraries were generated from the total RNA using ScriptSeq complete gold low 
input kit (Epicenter Biotechnologies, USA). All libraries were constructed according to 
manufacturer’s instructions and Ribo-Zero reagents were used to remove ~99% of rRNA 
(Table 4S). 
Libraries were sequenced to an equivalence of 6 samples per lane of a HiSeq2500. 
Fastq files were processed using trim_galore to remove low quality bases, trim adaptors 
Page 8 of 30International Journal of Cancer
  9 
and fix paired-end reads. Processed reads were aligned to the human genome 
GRCh37.p11 by Tophat2.0.7, using the gencode.v17 genome annotation as a guide. 
Reads could align   a maximum of 5 times, with 2 mismatches. 
Alignment statistics (Table 4S) were ascertained using the samtools flagstat command 
and CollectRnaSeqMetrics program in the Picard software suite, version 1.56. 
Expression quantification and differential expression analysis (FDR of 0.01) were 
performed using cuffdiff, version 2.1.1, with multireads assigned using the –u parameter. 
Principal Component Analysis (PCA) was performed for all expressed protein-coding 
genes in OVC and OSCC samples, using the prcomp function in R.  
The DAVID Bioinformatics Database 6.7 web server was used to assess the 
functional enrichment of the significant differentially expressed genes between OVC 
and OSCC 20.  
 
Results  
DNA copy number analysis of OVC versus OSCC  
Between one and ten million reads per sample were generated for copy number 
analysis, equating to one read to every 300bp-3Kb, or 0.033X-0.33X coverage. Copy 
number karyograms were constructed from 57 OVC and 45 OSCC cases using 
CNAnorm 14. Individual karyograms representative of normal epithelium, OVC, 
OSCC and OSCC with verrucous architecture are shown in Figure 2.  In general, 
visual inspection of OSCC karyograms showed more whole chromosome and 
localized gain and loss and a higher degree of aneuploidy across the whole genome 
when compared to OVCs. Cumulative frequency karyograms and GISTIC heatmaps 
for each tumour type are shown in figure 3.  
OSCC and indeed SCC from other sites have characteristic genomic features such 
as gains in chromosomal arms 3q, 5p, 7p, 8q and 20p, and losses in 3p, 4p, 8p, and 
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18q 21, 22. All these chromosomal abnormalities were seen in our OSCC tumours but 
none was detected in the OVC group. However, OVC has its own characteristic 
features, namely: gains of 7q11.2, 7q22, 3p21, 15q15, 16q22, and 17q23. 
Chromosomal losses were infrequent in OVC but detected at 6p21 and 17q12. 
Samples of OSCC with verrucous architecture all showed karyograms consistent 
with classical OSCC. 
Visual inspection of individual and cumulative karograms indicated that there was a 
substantial difference between the copy number landscape of OVC and OSCC 
genomes. We tested this by applying a novel logistic regression method that blindly 
predicts the subtype of an ‘unknown’ sample based on the copy number of two 
groups of ‘known’ samples. Of the 45 OSCC samples, four were misclassified, 
whereas only one out of 57 OVC samples was incorrectly predicted. 
Mutation detection in OVC compared to OSCC 
Exome sequencing data was produced from the tumours and matched adjacent 
normal epithelium for 12 OVC and 20 OSCC patients. Two OVC patients were 
excluded due to evidence of severe DNA damage resulting from tissue fixation i.e 
low coverage, high mismatch rate, and disproportionally high ratio of C/T 
mismatches. The remaining patients’ tumour DNAs were sequenced to an average 
of 90X coverage. 
From the 12 OVC patients, a total of 224 somatically mutated genes passed filters, 
ranging from between nine (V-123-01) to 53 (V-116-01) genes per patient. OVC 
patients’ individual mutation profiles are listed in Table 2S. From the 20 OSCC 
patients, 1347 mutated genes passed filters, ranging from 32 (PG-105) to 143 (PG-
144) per patient. 
For both tumour cohorts the most frequently occurring mutations are listed in Table1. 
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The top five genes (TP53, CDKN2A, NOTCH1, NOTCH2 and FAT1) in the OSCC 
cohort have previously been identified as significant HNSCC cancer genes 23, 24. 
None of these genes was found to be mutated in the OVC cohort. However, four 
genes (DSPP, MUC4, NEFH, ANP32E) were mutated in the verrucous cohort with a 
frequency greater than 30% (Table1 and Table 2S). These genes were not unique to 
OVC, being also detected at lower frequencies in our OSCC cohort (Table1) 
although not detected in other HNSCC exome studies 23, 24.  
For verrucous carcinoma, no genes were mutated in over 50% of patients. 
Nonetheless, the use of DAVID functional analysis revealed involvement of 
significant number of OVC mutated genes involved in cell adhesion and keratinocyte 
proliferation (Table 3S), while mutated genes in the OSCC cohort were more 
involved in cell death and apoptosis pathways (Table 3S). 
Gene expression in OVC compared to OSCC 
Gene transcription profiles were generated using RNA-Seq for all twelve OVC, with 
an average of 51412094 reads (ranging from 25602577 to 569763697), and with a 
median of 82% mapped reads. Ribosomal RNA ranged between 0% - 0.1% of the 
total reads (Table 4S). Gene expression was quantified as FPKM (Fragments per 
Kilobase per million Mapped) for each protein-coding and non-coding gene. The 
threshold of 0.1 FPKM was used to determine whether or not a gene was expressed. 
Gene transcription data were similarly obtained from 16 OSCC samples. Significant 
differential expression lists for protein-coding genes in oral verrucous samples 
versus OSCCs are illustrated in Table 2. 
The use of DAVID functional analysis revealed that significant differentially 
upregulated genes in OVC versus OSCC are involved in keratinocyte differentiation 
and epithelium development (Table 5S), while the significant differentially 
upregulated genes in OSCC versus OVC were more involved in cell growth and 
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migration and angiogenesis (Table 5S). Principal Component Analysis (PCA) of all 
expressed protein-coding genes in OVC and OSCC revealed an evident separation 
of the two cohorts (Figure 4). 
Comparing genomic changes and expression levels 
The copy number and expression levels of all significantly differentially expressed 
genes were correlated. Most genes showed no link between expression and copy 
number. Only three genes, SERPINE1, CDH3 and PLA2G4D were both significantly 
overexpressed in OVC samples and found in recurrent regions of gain. 
Only one gene reported as mutated in the exome data was significantly differentially 
expressed. A missense variant in CXCL5 was reported in one OVC sample. This 
gene was under-expressed in OVC samples compared to OSCC. 
Discussion 
Clinically, OVC appear as exophytic masses with a verrucous surface but, less often, 
they may be relatively smooth. Furthermore OSCC can have a superficial verrucous 
appearance thus morphological features alone can lead to misclassification with 
consequences for patient management that many include unnecessary neck 
dissections 25. For this reason, new approaches are needed. Recognising that 
genomic changes drive tumour development, we reasoned that verrucous carcinoma 
with its more indolent natural history would have a simpler genotype compared to the 
more aggressive classical oral squamous cell tumours. In fact this had already been 
demonstrated superficially by flow cytometry studies 26: our intention was to define 
these genomic changes more precisely, providing information that could be 
developed for diagnostic biomarkers. Previously, we showed that whole genome 
sequencing at low coverage could reveal differences in HPV positive and negative 
head and neck cancers 10 and therefore we applied this approach, creating 
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karyograms to compare OVC and OSCC. Additionally we included exome 
sequencing and RNA-seq in our comparative analysis to provide further precision in 
defining genomic regions that distinguished the two oral cancer subtypes. This study 
represents the largest and ‘first’ study, to date, to inspect genomic copy number 
patterns, somatic gene mutations and transcriptional changes that occur in OVC and 
compare them with the copy number, mutational and transcriptional events found in 
OSCC. All earlier studies on OVC were either case reports or immunohistochemistry 
studies. 
The rarity of these lesions makes them difficult to investigate and previous 
immunohistochemistry studies on oral verrucous lesions have yielded mixed results 
27, 28. Variations in samples, sample numbers, staining procedures and analysis 
methods, along with difficulties in defining ‘gold-standard’ histological criteria for 
diagnosis may explain the lack of concordance between these studies. 
Consistent with the analyses by flow cytometry 26, visual examination of the 57 OVC 
CN traces revealed a lower level of genomic damage when compared with 45 OSCC 
samples. This suggests that OVC is characterised by a lower degree of 
chromosomal instability than OSCC. This lower level of chromosomal instability 
could be linked to the minimal or absent histological cytological atypia found in OVC 
29. We used logistic regression analysis to obtain statistical quantitation of the copy 
number differences, correctly identifying 56 out of 57 OVC samples and 41 out of 45 
OSCCs.  
Interestingly, losses were detected frequently in OSCC genomes but rarely in OVCs. 
Losses on chromosomal arms 3p, 4q, 9p and 18q, and gains on 3q, 5q, 8q, and 20p 
are chromosomal signatures commonly linked with OSCCs 21, 22 and were frequently 
identified in this OSCC cohort but were absent in OVC, suggesting that these CN 
alterations may be related to the more aggressive behaviour of OSCC. However, 
OVC karyograms revealed their own distinctive features that were consistent for the 
subtype, namely gains at 7q11.2, 7q22, and 17q23, as well as loss at 17q12 at a 
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frequency of ~50%. These changes have not been previously identified as common 
CN altered chromosome lesions in oral cancer.  
Comparison of the mutation profiles of the two sub-groups provided further evidence 
that they had distinguishable genotypes. Four genes are mutated in more than one 
OVC sample, suggesting that they may have a role in the development of OVC 
lesions. These genes are: DSPP gene (mutated in 40% of OVC cohort), MUC4, 
NEFH and ANP32E (mutated in 30% of OVC cohort). These four genes are also 
mutated in at least one OSCC sample and have all been seen in other cancers. 
Earlier studies reported up-regulation of DSPP along with other genes in 
histologically aggressive and poorly differentiated OSCC and in some oral epithelial 
dysplasia 30. Other studies have demonstrated a positive correlation between MUC4 
expression and tumour growth and malignant progression in pancreatic lesions 31. 
NEFH was down-regulated along with other genes in metastatic lung squamous cell 
carcinoma samples when compared with non-metastatic samples 32. ANP32E 
expression was up-regulated in gastric cancer cells when compared with non-
neoplastic epithelial cells 33. All three OVC samples with an ANP32E mutation had 
missense mutations in exactly the same position, which makes this gene a strong 
candidate for a role in the development of oral verrucous tumours. ANP32E has a 
variant that has been reported to be associated with breast cancer development 34. 
Two of the four samples showing DSPP mutations exhibited identical in-frame 
deletions, as did two of the three were NEFH mutations. 
Interestingly, analysis of the exome data for all ten OVC samples showed no 
mutations within the TP53, CDKN2A, NOTCH1, NOTCH2 and FAT1 genes, all of 
which were frequently mutated in OSCC samples in this study and previously 
published work 23, 24. In particular, mutation of the tumour-suppressor, TP53 gene, is 
among the earliest identified genetic changes and the most common in HNSCC, 
arising in over half of all cases 35. No mutations were found in any of the ten OVC 
samples. The most recent gene expression study compared six patients with primary 
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OSCC and five patients with primary OVC using microarray technology 36. Of the 167 
differentially expressed genes (DEGs) reported, 39 were shared between OSCC and 
OVC, and eight (HLF, TGFBI, SERPINE1, MMP1, INHBA, COL4A2, COL4A1, and 
ADAMTS12) were significantly differentially expressed between the two groups. 
Seven of the eight were up-regulated in OSCC compared to OVC, with only HLF 
being comparatively up-regulated in OVC. For all eight significantly differentially 
expressed genes between the two groups previously reported, similar significant 
expression changes were observed for in our study, with HLF being the only gene 
from that previous list significantly up-regulated in OVC compared to OSCC. HLF is 
thought to be tumour suppressor gene that plays a role in the detoxification 
processes 37.  
Several of the genes differentially expressed between the two groups offer plausible 
explanations for the relatively benign nature of OVC lesions, and their 
correspondingly low metastatic potential, when compared to classical OSCC.  
The TNFRSF12A, IGFBP6, FSTL3, SMR3B and LAMC2 protein coding genes have 
previously been reported as highly expressed in head and neck cancer 38, 39, 40, 41, 
42, 43. These were overexpressed in the OSCC cohort compared to the OVC 
samples. In contrast, down regulation of the DLG2, HBB, and DSC1 genes has been 
associated with progression 44, 45, 46.  These were all expressed more highly in the 
OVC samples. Similarly, KRT76 and KRT2 have been reported to be down regulated 
in OSCC 47 and were again more highly expressed in our OVC samples. 
Amongst genes associated with metastasis, down regulation of HPGD has been 
shown to be a marker for metastasis 48. This gene is more highly expressed in the 
OVC cohort. In contrast, over expression of CXCL5, THBS1, MT2A and MT1X has 
been linked to metastasis 49 50 51. All of these genes were more highly expressed in 
the OSCC cohort. 
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DAVID functional enrichment and pathway analysis on RNA and exome sequencing 
OVC data revealed that a significant number of the differentially expressed genes 
and mutated genes are located in the plasma membrane, participate in cell 
adhesions and keratinocyte differentiation, and implemented in calcium ion (Ca2+) 
binding. On the other hand, the OSCC data revealed that the majority of the up-
regulated and mutated genes located in the cytoskeleton, participated in cell 
adhesion and migration, angiogenesis and cell death, and were implemented in 
nucleotide and growth factor binding. 
We have undertaken to better define the genomic and transcriptomic changes 
associated with oral verrucous carcinoma, and compare them to the changes 
observed in a similar group of classical oral squamous cell carcinomas. We used the 
three independent, complementary techniques of copy number sequencing, exome 
sequencing and RNA sequencing. For all three methods, there were clear 
differences that distinguish the OVC and OSCC cohorts. Taken together, these three 
independent analyses offer persuasive evidence that OVC should not be classified 
as a subtype of OSCC, but should be considered a separate disease entity. 
Using a number of genomic platforms, it has recently been shown that tumours are 
not always closely related by tissue of origin 4.  We have shown here that this applies 
to these two tumours, verrucous and squamous, both arising in the oral cavity. 
Verrucous carcinoma although rarely metastatic can be locally destructive and 
invasive and may benefit from therapeutic approaches in addition to surgery. The 
genomic and transcriptomic changes described here may suggest routes to the 
identification of a drug target, specific for these verrucous tumours. It would be of 
interest to determine if verrucous carcinomas that occur at other tissue sites share 
the same molecular signatures as those we have described for the oral cavity and 
possibly grouped together for the identification of treatment targets.  
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Tables 
 
Table1: 
Frequently occurring mutations in OVC and OSCC cohorts 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genes Mutated in OSCC Percentage  Mutated in OVC Percentage  
TP53 Yes 70% No  
CDKN2A Yes 35% No  
NOTCH1 Yes 10% No  
NOTCH2 Yes 25% No  
FAT1 Yes 20% No  
DSPP Yes 5% Yes 40% 
MUC4 Yes 15% Yes 30% 
NEFH Yes 20% Yes 30% 
ANP32E Yes 5% Yes 30% 
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Table 2: 
Significant differential expression list for protein-coding genes in oral verrucous 
samples versus OSCCs. Log FC refers to the log of the fold change. P.adj is the 
adjusted p-value. Positive log fold change indicates genes overexpressed in OVC, 
while negative values indicate genes overexpressed in OSCC. 
 
 
Gene Name Gene Function Log FC P.adj 
UNC45B Myoblast fusion 5.73176541 1.02E-09 
ANKRD30BL - 5.068125637 3.00E-09 
KRT2 Keratin gene, 
involved in 
differentiation 
3.28887873 4.25E-07 
DLG2 Guanylate kinase 3.142861272 3.25E-06 
RP11-181C3.1 - 2.589914427 4.46E-06 
KRT76 Keratin gene, 
structural integrity 
of epithelial cells 
4.393647354 4.37E-05 
LOR Keratinocyte cell 
envelope protein 
3.696791035 0.000182642 
ELOVL4 Elongates fatty 
acids 
1.913915467 0.000341653 
HTRA3 Probable serine 
protease 
-1.624779995 0.000341653 
PDK4 Glucose 
metabolism 
-2.442699908 0.000497839 
FLG2 Filaggrin family 4.155257725 0.000682528 
MT2A Binds heavy metals -2.067002668 0.000737808 
HPGD Prostoglandin 
inactivation. Inhibits 
proliferation in 
colon cancer. 
1.75292207 0.00078544 
TNFRSF12A Induces apoptosis, 
promotes 
angiogenesis, may 
modulate cell 
adhesion to matrix 
proteins. 
-1.923891955 0.000790342 
IGFBP6 Affects growth-
promoting effects of 
insulin-like growth 
factors. 
-2.386076713 0.000966215 
ATP10B - 1.718836376 0.001069055 
HBB Affects blood 
pressure 
3.554687453 0.001114319 
SLC11A1 Iron metabolism, -1.677099745 0.001188788 
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pathogen 
resistance. 
FDCSP Binds to surface of 
B-lymphoma cells 
3.705508687 0.001313018 
FSTL3 Bone formation, 
differentiation of 
haemopoietic 
progenitor cells 
-1.641022383 0.001395803 
PTGDR2 Prostoglandin 
receptor 
2.991133602 0.001395803 
DSC1 Keratinisation of 
epithelial tissue. 
2.515586707 0.001634268 
TCAP Muscle assembly -4.437644385 0.001634268 
DDIT4 Promotes neuronal 
cell death. 
-2.274816537 0.002274577 
INPP5F Decreases AKT 
and GSK3B 
phosphorylation. 
2.093068765 0.002500484 
PID1 - 1.742685358 0.002934709 
ENTPD3 ATD/ADP 
hydrolysis 
1.037851739 0.002934709 
PLA2G4D Inflammation 2.117301287 0.003105351 
CTC-236F12.4 - 1.109388981 0.003105351 
PDLIM3 Actin organisation -2.03957167 0.003434804 
C10orf53 - 2.290929173 0.004033844 
THBS1 Cell-cell and cell-
matrix interations. 
-2.189567433 0.005454379 
CXCL5 Neutrophil 
activation. 
-2.570674984 0.006168571 
SERPINH1 Collagen binding. -1.43209521 0.007136242 
MT1X Binds heavy 
metals. 
-1.54913047 0.007136242 
WNT9A Probable 
developmental 
protein. 
-1.802040084 0.007747887 
LCE1A Precursor of 
stratum corneum 
2.964477071 0.008599762 
LAMC2 Migration, 
attachment and 
organisation of cells 
in embryonic 
development. 
-2.28993045 0.008730485 
CYC1 Mitochondrial 
activity 
-1.369128527 0.008958146 
SMR3B Androgen regulated 
protein. 
-3.661364151 0.009270752 
HLF Member of PAR 
family. 
1.349932377 0.009352683 
CTGF Cell proliferation, 
differentiation and 
adhesion. 
-1.972202278 0.009409324 
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Figure legends: 
 
 
Figure 1: Photomicrographs of oral SCC with papillary architecture (a and b) and 
OVC (c, d, e and f). 
(a): H&E stain of oral SCC with papillary architecture at low power (magnification: 
x25 approximately), but with cytological atypia and invasion present (b) seen at 
magnification: x100 approximately. (c): H&E stain showing OVC classical features at 
low power (magnification: x40 approximately) and without cytological atypia or 
invasion (d) seen at magnification: x100 approximately (e) seen at magnification: 
x200 approximately (f) seen at magnification: x250 approximately. 
 
Figure 2: 
Examples of the genomic profiles (karyograms) of a. histologically normal oral 
epithelium (a patient with an ulcerative lesion), b. OVC, c. OSCC, d. OSCC with 
papillary architecture. Each data point represents one window of approximately 400 
reads. Genomic position is on the x-axis and tumour:normal ratio is on the y-axis. 
The black lines are regions of common copy number between breakpoints. Windows 
of gain and loss are red and blue respectively. Purple and orange arrows 
respectively point to chromosomal gains and losses common to that tumour type. 
 
Figure 3: 
Frequency of genomic gain and loss for OVC (a) and OSCC (b). Genomic position is 
on the x-axis, frequency (%) of gains (red) and losses (blue) are shown on the y-
axis. Heat map images of OVC (c) and OSCC (d) based on total segmented DNA 
copy number variation profiles. Heat map images were analysed using (GISTIC2.0). 
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In each heat map, the samples are arranged from left to right, and chromosomes are 
arranged vertically from top to bottom. Red represents CN gain and blue represents 
CN loss. 
 
Figure 4: 
Principal Component Analysis (PCA) biplot of PCs 1 and 2 using all expressed 
genes. This biplot best separates the two oral tumour groups: V –Verrucous 
carcinoma, and S – Squamous cell carcinoma. 
 
Supplementary: 
Table 1S: 
Patients’ clinical information. (-) stands for unknown information, (oral cavity) stands 
for unknown precise location within the oral cavity. 
 
Table 2S: 
OVC patients’ individual mutation profiles from exome sequencing. 
 
Table 3S:  
David functional analysis for the mutated genes harbouring putatively functional 
variants in OVC and OSCC cases. 
 
Table 4S: 
Oral verrucous samples RNA alignment statistics. (N: normal, T: tumour). 
 
Table 5S: 
David functional analysis for differentially overexpressed genes in OVC and OSCC 
cohorts. 
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